recombinant humanized type III collagen + progestin

This combination therapy consists of intrauterine submucosal injections of recombinant humanized type III collagen and oral high-dose progestin (such as medroxyprogesterone acetate or megestrol acetate). It is being investigated for fertility-sparing treatment in women aged 45 or younger with endometrial cancer or atypical endometrial hyperplasia. The recombinant humanized type III collagen is intended to promote endometrial repair and regeneration, potentially enhancing the therapeutic environment for future pregnancy. The progestin component acts as the primary hormonal antineoplastic agent, targeting progesterone receptors to induce lesion regression and tumor remission. The collagen is administered via hysteroscopy at specific sites in the uterine cavity.

Other names

Recombinant Humanized Type III Collagen Lyophilized Fibers + High-dose Progestin